Full-Time

Member of Technical Staff

Applied AI

Latent Labs

Latent Labs

11-50 employees

Develops foundational AI for molecular biology

No salary listed

London, UK

Hybrid

Hybrid working is required, with on-site work at international partner locations as needed.

Category
AI & Machine Learning (1)
Required Skills
Neural Networks
Machine Learning
Data Engineering
Version Control
Cell Biology

Get referred to Latent Labs

See people who can refer or advise you

Requirements
  • You have strong machine learning research experience in generative modelling, including a deep understanding of generative model architectures, training dynamics and inference behaviour.
  • You have made notable contributions to machine learning projects through widely used open source libraries, significant product launches or high-impact publications, such as at NeurIPS, ICML, ICLR or Nature venues.
  • You write robust, tested and maintainable machine learning code and have experience using version control and code review systems.
  • You have experience building systems that serve large models via application programming interfaces and running inference on cloud hardware, including parallelising data and models across accelerators.
  • You can translate complex technical concepts into clear language for scientific and non-technical stakeholders.
  • You understand how machine learning libraries interact with hardware and data and can optimize deep learning models for training and inference speed.
  • You can context-switch between deep technical work and customer-facing engagements.
Responsibilities
  • Develop a deep working understanding of the generative models, including their architectures, training data, capabilities and limitations.
  • Collaborate in a joint codebase with research scientists, engineers and protein designers while maintaining high code standards.
  • Drive end-to-end technical deployment of models into customer environments by designing production-grade application programming interface integrations and model-serving infrastructure.
  • Adapt and fine-tune models to meet specific customer requirements while collaborating with the research team to ensure scientific rigour.
  • Build machine learning data pipelines for customer-specific inference, evaluation and feedback workflows.
  • Ensure deployments meet customer standards for security, performance and reliability.
  • Work with pharmaceutical and biotechnology partners to scope technical requirements, troubleshoot issues and deliver solutions.
  • Serve as the technical point of contact for assigned customers and build relationships with their scientific and engineering teams.
  • Plan and carry out model inference against biological targets with customer biology teams, learn from results and feed insights back to the models.
  • Gather and synthesize customer feedback into actionable insights for product, research and platform teams.
  • Create technical documentation, integration guides and best-practice resources.
  • Work on-site at international partner locations as needed.
  • Stay current with developments in machine learning, model serving and cloud-native tooling.
  • Develop a strong working understanding of protein and cell biology.
  • Participate in knowledge sharing, including organizing and presenting at an internal reading group.
  • Attend and present at conferences.
Desired Qualifications
  • Experience in computational biology or protein design, including machine-learning-driven biology projects and understanding of biological-modeling data challenges, evaluation paradigms and scientific workflows.
  • Experience delivering production enterprise software meeting enterprise-grade requirements for security, compliance, auditability and uptime.
  • Academic training in physics, biology, chemistry or another related natural science field.

Latent Labs builds foundational biology models that power generative AI for biology. It offers AI tools to help researchers design new antibodies, optimize existing enzymes, and advance genetic engineering. The models translate biological data into actionable designs and optimization suggestions for lab use, provided through collaboration with partners. The goal is to accelerate molecular biology by giving researchers AI-guided design and directions for experiments.

Company Size

11-50

Company Stage

Series A

Total Funding

$59.1M

Headquarters

London, United Kingdom

Founded

2023

Get referred to Latent Labs

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Latent-Y hit 67% target-level success across nine targets with single-digit nanomolar affinities.
  • NVIDIA and Nebius delivered over 4x training speedups and 60% faster inference March 2026.
  • UC Davis, LMU University Hospital, and TGen produced lab-validated designs without prior expertise.

What critics are saying

  • Latent-Y remains preclinical; animal studies and human trials are still ahead.
  • Free researcher access risks commoditizing Latent Labs before enterprise contracts convert.
  • Biosecurity scrutiny limits access and product scope as regulators watch dual-use biology closely.

What makes Latent Labs unique

  • Latent-Y launched March 23, 2026, autonomously designs antibodies from text prompts.
  • Latent-X2 generates drug-like antibodies and peptides; GenScript validates outputs experimentally January 27, 2026.
  • Latent Labs opened Latent-Y worldwide July 15, 2026, with free daily quotas.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Parental Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

43%

1 year growth

43%

2 year growth

64%
Business Wire
Mar 23rd, 2026
Latent-Y AI agent designs therapeutic antibodies in hours, 56x faster than expert teams

Latent Labs has launched Latent-Y, an AI agent that autonomously designs therapeutic antibodies from text prompts, reducing weeks of expert work to hours. The system is powered by Latent-X2, the company's frontier model for drug-like antibody and peptide design. Latent-Y operates independently, analysing target molecules, identifying viable epitopes, designing antibody candidates and validating them computationally. Scientists can run the agent fully autonomously or pause at each stage for review. The London and San Francisco-based company has demonstrated lab-validated results across three antibody design campaigns, including epitope discovery yielding nanomolar-affinity binders. User studies showed PhD-level experts completed design campaigns 56 times faster using Latent-Y compared to independent expert estimates. The platform is now available to selected partners through the Latent Labs platform.

PR Newswire
Jan 28th, 2026
GenScript partners with Latent Labs as wet-lab validator for AI drug discovery model Latent-X2

GenScript Biotech Corporation has announced its role as wet-lab partner for Latent Labs' Latent-X2, a next-generation AI model that designs antibodies and peptides with drug-like properties. GenScript provides high-throughput expression, purification and functional testing of AI-generated molecules, enabling rapid iteration between computational predictions and biological performance. Using its TurboCHO™ High Throughput Platform and cell-free expression systems, GenScript screens AI-designed antibodies, minibinders and peptides to compare candidates and collect data on developability and binding. This reduces reliance on iterative wet-lab optimisation. The collaboration addresses a key industry challenge by accelerating timelines whilst improving likelihood of clinical success. Founded in 2002, GenScript supports over 200,000 customers across 100-plus countries with a team of 5,500-plus employees.

Wow Partners, Inc.
Feb 13th, 2025
Latent Labs raises $50M for AI biology

Latent Labs, an AI-based biology platform developer, has emerged from stealth mode, securing $50 million in funding. The round was co-led by Radical Ventures and Sofinnova Partners, with participation from Flying Fish, Isomer, 8VC, Kindred Capital, and Pillar VC. Notable angel investors include Jeff Dean, Aidan Gomez, and Mati Staniszewski. Founded by Simon Kohl, a key figure in the Nobel Prize-winning AlphaFold2 project, Latent Labs aims to revolutionize drug development with generative AI technology.

TechCrunch
Feb 13th, 2025
Founded by DeepMind alumnus, Latent Labs launches with $50M to make biology programmable | TechCrunch

A new startup from one of the key scientists at Google DeepMind exits stealth today with $50 million in funding.

Business Insider
Aug 8th, 2023
DeepMind's secret mafia: Meet the stealth startups emerging from Google's AI lab

Alphabet's AI research lab DeepMind nurtures the industry's top talent. It's also spawned a wave of secretive new startups.